CI

At a glance

ClinicalIndex Comparison Record
Phase 2Active· 78 enrolled
Drug / intervention
Carboplatin +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03414684
NCT03414684Phase 2Active
CompareCT.gov

A Randomized Phase II Trial of Carboplatin With or Without Nivolumab in First-line Metastatic Triple-negative Breast Cancer

Dana-Farber Cancer Institute·interventional·Posted Jan 30, 2018·Updated Sep 29, 2025

In Brief

A Phase 2 clinical trial evaluating Carboplatin and Nivolumab for Breast Cancer. Active but no longer recruiting, targeting 78 participants across 10 sites.

Detailed Summary

This research study is studying a drug called Carboplatin with or without another study drug, Nivolumab as a possible treatment for triple-negative breast cancer that has spread to other parts of the body. The interventions involved in this study are: * Carboplatin * Nivolumab

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBreast Cancer
CountriesUnited States
CollaboratorsBristol-Myers Squibb

Timeline

Phase 2Active
201820192020202120222023202420252026
First PostedJan 30, 2018
Enrollment StartJan 30, 2018
Primary CompletionSep 28, 2021
Study CompletionJul 30, 2026
TodayJul 2, 2026
Enrollment to primary: 3.7 yearsPosted 8.4 years ago

Interventions

Carboplatindrug

Carboplatin interferes with the development of the genetic material in a cell, which will cause the cancer cells to die.

Nivolumabdrug

Nivolumab works by attaching to and blocking a molecule called PD-1. PD-1 is a different molecule that can turn off the immune system by interacting with PD-L1 on the cancer cells